DexCom, Inc. $DXCM Stock Position Lifted by Gradient Investments LLC

Gradient Investments LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 372,542 shares of the medical device company’s stock after purchasing an additional 53,283 shares during the period. Gradient Investments LLC owned approximately 0.10% of DexCom worth $25,091,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Brighton Jones LLC raised its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC boosted its holdings in shares of DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares in the last quarter. Focus Partners Wealth increased its stake in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares during the period. Finally, NewEdge Advisors LLC increased its stake in shares of DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after acquiring an additional 258 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

NASDAQ DXCM opened at $84.75 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $87.85. The company has a market cap of $31.98 billion, a PE ratio of 33.50, a PEG ratio of 1.39 and a beta of 1.41. The stock’s 50-day moving average price is $74.42 and its two-hundred day moving average price is $69.73.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the company posted $0.48 earnings per share. On average, analysts predict that DexCom, Inc. will post 2.65 EPS for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of research analyst reports. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Barclays reiterated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Sanford C. Bernstein set a $77.00 price objective on DexCom in a research note on Friday, May 1st. UBS Group set a $96.00 price objective on DexCom and gave the company a “buy” rating in a report on Tuesday, July 28th. Finally, Bank of America decreased their target price on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Activity

In related news, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 102,506 shares of company stock valued at $7,535,898 in the last 90 days. Company insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.